Five-alpha reductase inhibitor use and risk of kidney and bladder cancer in men with benign prostatic hyperplasia: A population-based cohort study
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY（2022）
摘要
The findings of this study indicate that 5-alpha reductase inhibitors are unlikely to reduce kidney or bladder cancer risk.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要